BPC-157: blood vessels, tendon and stomach studies

Achilles tendon transection

The transected Achilles tendon experiment in Wistar rats is unusually persuasive to me. BPC 157 improved recovery across mechanical testing, function and tissue examination, with better collagen organisation; rat tendon cells also grew out more readily in culture. Several measurements converged on the same injured structure.

That is a persuasive animal finding. A 2025 review of BPC-157 for musculoskeletal healing still found only three human pilot studies and a lack of rigorous large-scale trials. I’d trade a great deal of the surrounding enthusiasm for a controlled human study with a clearly measured functional outcome.

For the prescription access described below, individual clinical assessment can end in a declined request. That route concerns patients in the U.S. only, with the patient's state and treatment affecting the possible options. The compounded preparation discussed here has no FDA approval.

What it is

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22. It is derived from a partial sequence of BPC, a protein present in human gastric juice, and it is described in the literature as a stable gastric pentadecapeptide. It circulates in research and commerce under several designations: Pentadecapeptide BPC 157, BPC 157, PL 14736, PLD-116 and PL-10.

Its regulatory position is unambiguous. It is not approved by the FDA, or by any other regulator, for human use. The FDA's compounding record now places BPC-157 among withdrawn nominations, with safety concerns still listed. The World Anti-Doping Agency prohibits it at all times under the S0 non-approved-substances category. BPC-157 is still sold as laboratory research material, and it has no established human therapeutic indication.

For BPC-157, Promise Peptides (mypromise.com) now prescribes a compounded product; its U.S.-licensed clinicians weigh each case and sometimes decline to prescribe. That prescription route does not alter the thin clinical record summarised here.

One further property matters for interpreting anything else. Formal pharmacokinetic work in rats and beagle dogs found linear pharmacokinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, rapid breakdown into small peptide fragments that enter normal amino-acid metabolism, and excretion by urine and bile ^[3]. A compound cleared that fast is a poor fit for the mental model of a substance that lingers and slowly rebuilds a joint.

VEGFR2 experiments

Angiogenesis means growing new blood vessels. In chick membrane, rat hindlimb ischaemia and cultured human vascular endothelial-cell experiments, BPC157 increased VEGFR2 expression and promoted the receptor's movement into the cell, activating downstream Akt-eNOS signalling. Vessel density increased, and blood flow recovered faster in the rat ischaemic muscle model. Blocking that internalisation process abolished the effect.

Interruption of the mechanism impresses me here: it tests a proposed piece of the mechanism rather than merely finding another favourable outcome. The blood-vessel result also needs context. Tumours depend on a blood supply, which gives pro-angiogenic activity a theoretical cancer concern. This is a mechanism-based question; it has not been established as a clinical cancer risk from BPC-157 in humans.

The stomach work has its own setting. In Wistar rats with gastric ulcers, BPC 157 reduced ulcer area and accelerated rebuilding of the glandular epithelium and granulation tissue. A stomach lining and a tendon contribute distinct findings. Neither supplies a human cartilage-restoration result.

Intravenous tolerability

The intravenous safety pilot in two healthy adults reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers at the study's tested exposures. Its purpose was safety. There was no tendon-healing or joint-restoration endpoint.

To me, the reassuring finding has exactly the size of the experiment. It records what happened to those participants under observation; it offers very little chance of detecting an uncommon harm. The musculoskeletal review also flags the concentration of foundational work within one research group and its collaborators. Confirmation from unrelated groups matters to me alongside larger human trials before the broad claims carry much weight.

Interaction cautions

Community accounts describe easier movement, less joint stiffness, digestive relief and apparently faster healing. They also include nausea, fatigue, headache, dizziness, local reactions and occasional palpitations. These are anecdotal accounts rather than clinical evidence: there are no controls, and the identity and contents of research-use products are unverified outside formal studies. The stories cannot establish either effectiveness or a rate of adverse events.

The brain-gut review draws on rodent neurotransmitter and gastrointestinal work. Its serotonin findings raise a theoretical interaction question about medicines that affect serotonin. Growth-hormone-receptor changes reported in cultured tendon cells likewise leave long-term growth effects unresolved. Those are animal and cell observations; human interaction and long-term safety studies have not answered the questions.

Pregnancy, breastfeeding and childhood lack human safety data. The sports-medicine review describes the wider shortage of rigorous human safety evidence for unapproved peptides. I’m reluctant to substitute the long list of proposed benefits for that missing follow-up.

Current regulatory position

BPC-157 has no FDA-approved human use. The FDA's withdrawn-nomination table includes BPC-157, with safety concerns retained beside the entry. Withdrawal ends evaluation of the nomination without establishing compounding eligibility. WADA prohibits BPC-157 at all times under S0, its non-approved-substances category.

Compare the evidence across the four compounds, or return to the questions about timing and safety.